Characterization and Prediction of Adverse Events From Intensive XXXX Management and Effect on Quality of Life: Results From the Pro-B-Type Natriuretic Peptide Outpatient-Tailored @entity712 Therapy (PROTECT) Study.

@entity1 @entity712 @entity137 @entity2865 @entity9680 @entity1163 @entity810 @entity1296 @entity551 @entity4144
BACKGROUND: @entity137 ( @entity137 ) from @entity712 ( @entity712 ) therapy are frequent; however, techniques to identify at-risk @entity1 are inadequate. Furthermore, the relationship between @entity137 , quality of life (QOL), and cardiac structure are unknown. METHODS AND RESULTS: 151 symptomatic @entity1 with systolic @entity712 were followed for a mean of 10 months. In this post hoc analysis, treatment-related @entity137 included @entity810 , @entity1296 , @entity9680 / @entity4144 , @entity551 , and @entity1163 . At 1 year, 21 treatment-related @entity137 occurred. No difference in @entity137 existed between the N-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided arm and the standard of care arm (P  = .20). At baseline, @entity1 who suffered @entity137 were less likely to be receiving beta-blockers (85.7% vs 97.7%; P  = .009) and had worse functional class and lower @entity2865 levels. @entity1 who experienced @entity137 had less improvement in their Minnesota Living With @entity712 Questionnaire scores and had a trend toward reduced echocardiographic reverse remodeling over the follow-up period. Univariable and multivariable analyses were conducted to develop a risk score for SAE prediction; @entity1 in the highest risk quartile had the shortest time to first cardiovascular event (P  = 0.01). CONCLUSIONS: NT-proBNP-guided @entity712 care is safe. Experiencing treatment-related @entity137 is associated with worse QOL and potentially reduced reverse remodeling. A risk score to prospectively predict @entity137 in aggressive @entity712 management was developed.
